GeneReach Biotechnology Corp. - Laporan Laba Rugi (TTM)

GeneReach Biotechnology Corp.
TW ˙ TPEX ˙ TW0004171004
NT$ 29.20 ↑0.35 (1.21%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi GeneReach Biotechnology Corp. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 695 857 961 979 1,075 1,012 1,015 1,063 886 750 583 314 256 225 203 192 206 206 213 224
Change (%) 23.30 12.08 1.91 9.83 -5.87 0.31 4.70 -16.60 -15.39 -22.33 -46.18 -18.38 -11.90 -9.88 -5.47 7.43 0.07 3.18 5.32
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 166 222 240 240 290 265 273 306 246 260 250 208 209 198 175 142 141 88 82 79
Change (%) 33.19 8.09 0.39 20.47 -8.48 2.95 12.01 -19.67 5.85 -3.78 -17.01 0.72 -5.36 -11.41 -19.01 -0.93 -37.29 -7.17 -4.09
% of Revenue 23.93 25.86 24.93 24.56 26.94 26.19 26.88 28.76 27.70 34.66 42.94 66.21 81.71 87.77 86.28 73.91 68.17 42.72 38.44 35.00
Gross Operating Profit 529 635 721 739 786 747 742 757 641 490 332 106 47 28 28 50 66 118 131 146
Change (%) 20.19 13.48 2.42 6.37 -4.91 -0.63 2.01 -15.37 -23.53 -32.17 -68.13 -55.82 -41.07 1.08 79.69 31.11 80.05 10.90 11.20
% of Revenue 76.07 74.14 75.07 75.44 73.06 73.81 73.12 71.24 72.30 65.34 57.06 33.79 18.29 12.23 13.72 26.09 31.83 57.28 61.56 65.00
SG&A 189 211 207 220 211 208 210 201 199 190 182 177 182 195 192 188 184 169 167 171
Change (%) 11.97 -1.84 5.88 -3.81 -1.51 0.86 -4.41 -0.89 -4.45 -4.29 -2.88 3.23 7.23 -1.60 -2.48 -1.68 -8.34 -1.11 2.05
% of Revenue 27.14 24.65 21.59 22.43 19.64 20.55 20.67 18.87 22.42 25.32 31.21 56.30 71.21 86.67 94.64 97.63 89.34 81.83 78.44 76.00
R&D 68 69 64 56 55 57 54 59 60 59 59 55 58 61 75 77 79 81 73 75
Change (%) 0.95 -6.48 -13.68 -1.21 3.19 -5.12 10.58 0.44 -1.42 0.19 -6.10 4.78 6.01 21.92 2.70 2.67 1.90 -9.27 3.27
% of Revenue 9.80 8.03 6.70 5.67 5.10 5.59 5.29 5.59 6.73 7.84 10.12 17.65 22.65 27.26 36.88 40.06 38.29 38.99 34.29 33.62
OpEx 423 502 511 516 556 530 536 566 504 509 491 439 449 455 443 406 404 338 322 325
Change (%) 18.54 1.91 0.85 7.79 -4.68 1.27 5.45 -10.90 0.93 -3.51 -10.47 2.24 1.21 -2.69 -8.15 -0.59 -16.42 -4.64 0.77
% of Revenue 60.88 58.53 53.22 52.66 51.69 52.34 52.84 53.22 56.86 67.82 84.26 140.16 175.58 201.70 217.79 211.61 195.80 163.55 151.16 144.62
Operating Income 272 355 449 463 519 482 479 497 382 241 92 -126 -193 -229 -239 -214 -198 -131 -109 -100
Change (%) 30.70 26.44 3.12 12.10 -7.15 -0.74 3.85 -23.09 -36.89 -62.01 -237.32 53.59 18.55 4.38 -10.43 -7.79 -33.62 -16.93 -8.14
% of Revenue 39.12 41.47 46.78 47.34 48.31 47.66 47.16 46.78 43.14 32.18 15.74 -40.16 -75.58 -101.70 -117.79 -111.61 -95.80 -63.55 -51.16 -44.62
Interest Expense -3 -4 -4 -5 -6 -6 -7 -7 -7 -7 -7 -7 -6 -6 -5 -5 -5 -6 -6 -7
Change (%) 17.12 10.66 10.96 22.23 9.32 5.92 4.05 -5.75 1.64 1.06 1.50 -7.11 -8.55 -7.17 -5.29 6.83 9.65 7.41 6.13
% of Revenue -0.47 -0.45 -0.44 -0.48 -0.53 -0.62 -0.65 -0.65 -0.73 -0.88 -1.15 -2.16 -2.46 -2.56 -2.63 -2.64 -2.62 -2.87 -2.99 -3.01
Net Income 181 257 337 362 404 377 383 411 338 221 84 -99 -161 -166 -149 -139 -142 -119 -109 -139
Change (%) 41.85 31.02 7.41 11.57 -6.76 1.80 7.15 -17.83 -34.43 -61.96 -217.53 62.30 3.52 -10.26 -6.59 1.55 -16.12 -8.36 27.50
% of Revenue 26.09 30.02 35.09 36.99 37.57 37.21 37.77 38.65 38.08 29.51 14.45 -31.56 -62.77 -73.75 -73.44 -72.57 -68.60 -57.50 -51.07 -61.83

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista